NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Jun 02 2025

0mins

Clinical Trial Results: NervGen Pharma's NVG-291 showed promising results in a Phase 1b/2a trial for spinal cord injury, meeting one co-primary endpoint by improving motor connectivity and hand function in patients compared to placebo.
Safety and Tolerability: The drug was generally safe with mild/moderate injection site reactions reported; no serious adverse events or treatment discontinuations occurred in the NVG-291 group.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.